Clinical utility of urinary markers of bone turnover in response to antiresorptive therapies

Endocrinologist

Volumn 13, Issue 3, 2003, Pages 293-299

  Dulipsingh, Latha ^a   De Souza, Mary Jane ^b   Ikram, Zahed ^c   Fall, Pamela ^e   Willard, Alice ^d   Fang, Zixing ^c   Prestwood, Karen ^c   Raisz, Lawrence ^c  

^a NEW BRITAIN GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e Univ of Connecticut Health Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; OSTEOLYSIS; OSTEOPOROSIS; UNITED KINGDOM; URINALYSIS; URINE LEVEL;

EID: 0038266863     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000081697.21823.61     Document Type: Article

References (15)

1. Delmas PD: Biochemical markers of bone turnover. J Bone Min Res 1993;8:S549-55.
2. Taylor AK, Leuken SA, Libanati C, Baylink DJ: Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994;20:589-607.
3. Delmas PD: Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteo Int 1993;1S:81-6.
4. Kushida K, Takahashi M, Kawana K, Inoue T: Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 1995;80:2447-50.
5. Jenkins DK: Deoxypyridinoline and telopeptides compared. Metra Biosystems 1998.
6. Gertz BJ, Clemens JD, Holland SD, et al.: Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 1998;63:102-6.
7. Miller PD, Baran DT, Bilezikian JP, et al.: Practical clinical application of biochemical markers of bone turnover. J Clin Densitometry 1999;2:323-42.
8. Hannon R, Blumsohn A, Naylor K, Eastell R: Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Min Res 1998;13: 1124-33.
9. Flesis JL. Design and Analysis of Clinical Experiments. Hoboken, NJ: John Wiley & Sons, Inc.; 1986.
10. Machado ABDC, Hannon R, Eastell R: Monitoring alendronate therapy for osteoporosis. J Bone Min Res 1999;14:602-8.
11. Prestwood KM, Gunness M, Muchmore DB, et al.: A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. JCEM 2000;85:2197-202.
12. Raisz LG, Smith JA, Prahiotis M, Fall P, et al.: Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover. Osteoporosis Intl 2000;11:615-20.
13. Rogers A, Hannon RA, Eastell R: Biochemical markers as predictors of rates of bone loss after menopause. J Bone Min Res 2000;15:1398-404.
14. Draper MW, Flowers DE, Huster WJ, et al.: A controlled trial of raloxifene hydrochloride: impact on bone turnover and serum lipid profile in healthy post menopausal women. J Bone Min Den 1996;11:834-42.
15. Garnero P, Shih WJ, Gineyts E, et al.: Comparison of new biochemical markers of bone turnover in late menopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.